Jazz Pharmaceuticals Therapeutics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Celator Pharmaceuticals, Inc. (to 2025)
5
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 5, 2027The maintenance fee for Assays and Methods for Selecting a Treatment Regimen for a Subject with Leukemia (US 11,746,386) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due Apr 17, 2027The maintenance fee for Inhibiting Ataxia Telangiectasia and RAD3-RELATED Protein (ATR) (US 11,787,781) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due Jun 17, 2027The maintenance fee for Remote Loading of Sparingly Water-Soluble Drugs into Liposomes (US 10,507,182) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Inhibiting Ataxia Telangiectasia and RAD3-RELATED Protein (ATR) (US 10,570,119) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 1 fee due Sep 1, 2027The maintenance fee for Compositions for Delivery of Drug Combinations (US 9,271,931) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
- 1 fee due Nov 14, 2027The maintenance fee for Treatment of Hematological Disorders (US 11,980,636) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Sep 15 US 12,734,181 Methods for Preparing Liposomal Formulations
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,850,990 | Compositions for Delivery of Drug Combinations In force · Medium confidence | In force | Medium confidence | |
| US 8,022,279 | Liposomal Formulations of Anthracycline Agents and Cytidine Analogs In force · Medium confidence | In force | Medium confidence | |
| US 7,842,676 | Fixed Ratio Drug Combination Treatments for Solid Tumors In force · High confidence | In force | High confidence | |
| US 8,092,828 | Fixed Drug Ratios for Treatment of Hematopoietic Cancers and Proliferative Disorders In force · High confidence | In force | High confidence | |
| US 8,044,052 | Biaryl Ether Urea Compounds In force · High confidence | In force | High confidence | |
| US 9,271,931 | Compositions for Delivery of Drug Combinations In force · Medium confidence | In force | Medium confidence | |
| US 10,028,912 | Method of Lyophilizing Liposomes In force · High confidence | In force | High confidence | |
| US 10,166,184 | Method of Lyophilizing Liposomes In force · High confidence | In force | High confidence | |
| US 10,835,492 | Method of Lyophilizing Liposomes In force · High confidence | In force | High confidence | |
| US 9,737,485 | Remote Loading of Sparingly Water-Soluble Drugs into Liposomes In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 28: 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.